Saira Ramasastry sold $139k of MIRM
director at Mirum Pharmaceuticals, Inc.. 2,000 shares at an average of $69.73, traded Dec 18, 2025, filed Dec 19, 2025.
Score components
- +15RoleDirector
- +11Trade size$139k at market
- +20Share of holdings soldSold 100% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +17.1%, 3m +13.9%, 6m +37.8%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001547959-25-000007, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 18, 2025 | MOption exercise Common Stock10b5-1 | +2,000 | $23.51 | $47k | 2,000 | Dec 19, 2025 |
| Dec 18, 2025 | SOpen-market sale Common Stock10b5-1 | -1,000 | $69.46 | $69k | 1,000 | Dec 19, 2025 |
| Dec 18, 2025 | SOpen-market sale Common Stock10b5-1 | -1,000 | $70.00 | $70k | 0 | Dec 19, 2025 |
| Dec 18, 2025 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -2,000 | $0.00 | $0 | 15,000 | Dec 19, 2025 |
Related signals
Other insiders at Mirum Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 52Moderate | Mirum Pharmaceuticals, Inc. | Eric Bjerkholt CHIEF FINANCIAL OFFICER | $978k 9,943 shares | -18% | |
| 38Weak | Mirum Pharmaceuticals, Inc. | Jolanda Howe SVP, GLOBAL CONTROLLER | $66k 658 shares | -52% | |
| 35Weak | Mirum Pharmaceuticals, Inc. | Christopher Peetz CHIEF EXECUTIVE OFFICER | $3.0M 30,000 shares | -13% | |
| 60Notable | Mirum Pharmaceuticals, Inc. | Jolanda Howe SVP, GLOBAL CONTROLLER | $4.0M 40,000 shares | -97% | |
| 41Moderate | Mirum Pharmaceuticals, Inc. | Eric Bjerkholt CHIEF FINANCIAL OFFICER | $600k 6,001 shares | -14% | |
| 30Weak | Mirum Pharmaceuticals, Inc. | Christopher Peetz CHIEF EXECUTIVE OFFICER | $2.0M 20,000 shares | -9% | |
| 42Moderate | Mirum Pharmaceuticals, Inc. | Jolanda Howe SVP, GLOBAL CONTROLLER | $194k 1,840 shares | -59% | |
| 42Moderate | Mirum Pharmaceuticals, Inc. | Eric Bjerkholt CHIEF FINANCIAL OFFICER | $611k 5,000 shares | -11% | |
| 30Weak | Mirum Pharmaceuticals, Inc. | Christopher Peetz CHIEF EXECUTIVE OFFICER | $2.4M 20,000 shares | -9% | |
| 35Weak | Mirum Pharmaceuticals, Inc. | Jolanda Howe SVP, GLOBAL CONTROLLER | $327k 2,721 shares | -47% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.